Asoprisnil

Drugbox
IUPAC_name = rel-4- [(8R,11S,13R,14R,17R)-17-Methoxy-17-(methoxymethyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta [a] phenanthren-11-yl] benzaldehyde oxime

---

CAS_number = 199396-76-4
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 9577221
DrugBank =
chemical_formula =
C=28 | H=35 | N=1 | O=4
molecular_weight = 449.582 g/mol
smiles =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone sensitive myomata. [cite journal |author=DeManno D, Elger W, Garg R, "et al" |title=Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy |journal=Steroids |volume=68 |issue=10-13 |pages=1019–32 |year=2003 |pmid=14667995 |doi=]

In 2005, Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed. [ [http://www.schering.de/html/en/50_media/download/_files/2005/fin_rep/interim/05q3_areas_en.pdf Schering Interim Report Q1-3 2005] ]

References